EuBiologics Co., Ltd. (206650.KQ)
KRW 13100.0
(0.08%)
KRW 13100.0
(0.08%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.8 Billion KRW | -22.22% |
| 2022 | 3.6 Billion KRW | -10.0% |
| 2021 | 4 Billion KRW | -73.27% |
| 2020 | 14.96 Billion KRW | -39.7% |
| 2019 | 24.81 Billion KRW | 34.43% |
| 2018 | 18.46 Billion KRW | 664.25% |
| 2017 | 2.41 Billion KRW | -30.32% |
| 2016 | 3.46 Billion KRW | -43.29% |
| 2015 | 6.11 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 2.6 Billion KRW | -7.14% |
| 2024 Q2 | 2.4 Billion KRW | -7.69% |
| 2023 Q2 | 3.2 Billion KRW | -5.88% |
| 2023 Q3 | 3 Billion KRW | -6.25% |
| 2023 Q4 | 2.8 Billion KRW | -6.67% |
| 2023 Q1 | 3.4 Billion KRW | -5.56% |
| 2023 FY | 2.8 Billion KRW | -22.22% |
| 2022 Q2 | 4 Billion KRW | 0.0% |
| 2022 FY | 3.6 Billion KRW | -10.0% |
| 2022 Q4 | 3.6 Billion KRW | -5.26% |
| 2022 Q3 | 3.8 Billion KRW | -5.0% |
| 2022 Q1 | 4 Billion KRW | 0.0% |
| 2021 FY | 4 Billion KRW | -73.27% |
| 2021 Q3 | 4 Billion KRW | -73.79% |
| 2021 Q2 | 15.25 Billion KRW | 0.99% |
| 2021 Q4 | 4 Billion KRW | 0.0% |
| 2021 Q1 | 15.11 Billion KRW | 0.0% |
| 2020 FY | 14.96 Billion KRW | -39.7% |
| 2019 FY | 24.81 Billion KRW | 34.43% |
| 2018 FY | 18.46 Billion KRW | 664.25% |
| 2017 FY | 2.41 Billion KRW | -30.32% |
| 2016 FY | 3.46 Billion KRW | -43.29% |
| 2015 FY | 6.11 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 988.75 Million KRW | -183.184% |
| CMG Pharmaceutical Co., Ltd. | 19.06 Billion KRW | 85.313% |
| Celltrion Pharm, Inc. | 4.33 Billion KRW | 35.384% |
| Huons Global Co., Ltd. | 66.94 Billion KRW | 95.817% |
| DongKook Pharmaceutical Co., Ltd. | 18.74 Billion KRW | 85.067% |
| Enzychem Lifesciences Corporation | 1.02 Billion KRW | -173.171% |
| Humedix Co., Ltd. | 1.75 Billion KRW | -59.514% |
| Boditech Med Inc. | 2.09 Billion KRW | -33.337% |
| FutureChem Co.,Ltd | 2.61 Billion KRW | -6.879% |
| Huons Co., Ltd. | 58.35 Billion KRW | 95.201% |
| BNC Korea Co., Ltd. | 301.69 Million KRW | -828.104% |
| AptaBio Therapeutics Inc. | 13.56 Billion KRW | 79.365% |